<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04217993</url>
  </required_header>
  <id_info>
    <org_study_id>ZGJAK006</org_study_id>
    <nct_id>NCT04217993</nct_id>
  </id_info>
  <brief_title>Jaktinib Hydrochloride for the Treatment of Ruxolitinib Intolerance of Myelofibrosis</brief_title>
  <official_title>Jaktinib Dihydrochloride Monohydrate in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With Ruxolitinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase IIB, open-label, multicenter study evaluated the efficacy and safety of oral
      Jaktinib Dihydrochloride in Intermediate-risk and High-risk Myelofibrosis and Previously
      Treated With Ruxolitinib
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Jaktinib Dihydrochloride Monohydrate is a potent inhibitor of JAK1 and JAK2 that demonstrated
      efficacy and safty in preclinical study and safty in a phase 1 in healthy volunteer；This
      phase IIB, open-label, multicenter study evaluated the efficacy and safety of oral Jaktinib
      Dihydrochloride in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With
      Ruxolitinib
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2019</start_date>
  <completion_date type="Anticipated">September 18, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 18, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>The proportion of all subjects whose spleen volume decreased by 35% or more at 24 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>IWG-MRT efficacy criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anemia response rate</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Proportion of anemia response in all of anemia patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total symptoms score(TSS) response rate</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>TSS response is defined as the proportion of subjects who achieve a ≥ 50% reduction in TSS at the Week 24 compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>The time from the date of enrollment to the date on which any of the following events occurred：①Spleen volume increased by ≥25% compared to the lowest value recorded during the trial including baseline；②Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The time elapsed from the date of enrollment to the date of any of the following events：①The first bone marrow smear shows the date of ≥20% of the original cells；②The first peripheral blood smear showed ≥20% of the original cells and the absolute value of the original cells was ≥1×10^9/L for at least 2 weeks；③Death from any cause。</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Time elapsed from the date of enrollment to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>up to 28 weeks</time_frame>
    <description>Vital signs, physical examination, blood routine; severity and incidence of adverse events and adverse reactions (NCI-CTCAE V4.03)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombotic event rate</measure>
    <time_frame>up to 28 weeks</time_frame>
    <description>Arterial thrombosis：①Coronary heart disease；②Cerebral arterial thrombosis；③Peripheral arterial occlusive disease：Such as mesenteric artery thrombosis and extremity arterial thrombosis。Venous thrombosis：①Thrombophlebitis；②Deep vein thrombosis；③Pulmonary embolism。Microcirculatory thrombosis: ① thrombotic thrombocytopenic purpura; ② hemolytic uremic syndrome; ③ extracorporeal circulation thrombosis; ④other: such as fulminant purple epilepsy and disseminated intravascular coagulation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Jaktinib hydrochloride tablet 100mg twice a day.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is the dose group was given Jaktinib hydrochloride 100mg （2 tablets）dose group for twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Jaktinib hydrochloride tablet 150mg once a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is the dose group was given Jaktinib hydrochloride 150mg （3 tablets）dose group for once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Jaktinib hydrochloride tablet 100mg once a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is the dose group was given Jaktinib hydrochloride 100mg （2 tablets） dose group for once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jaktinib hydrochloride tablets</intervention_name>
    <description>Jaktinib hydrochloride tablets 100mg twice dose group and Jaktinib hydrochloride tablets 150mg qd dose group and Jaktinib hydrochloride tablets 100mg qd dose group</description>
    <arm_group_label>Jaktinib hydrochloride tablet 100mg once a day</arm_group_label>
    <arm_group_label>Jaktinib hydrochloride tablet 100mg twice a day.</arm_group_label>
    <arm_group_label>Jaktinib hydrochloride tablet 150mg once a day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age greater than or equal to 18 years old ,male or female;

          2. Patients diagnosed with Primary Myelofibrosis according to WHO standard (2016
             version), or patients diagnosed with Post-Polycythemia Vera Myelofibrosis or
             Post-Essential Thrombocythemia Myelofibrosis according to International Working Group
             Myeloproliferative Neoplasms Research and Treatment(IWG-MRT) standard. Both Janus
             Kinase 2(JAK2)mutation and JAK2 wild can be enrolled；

          3. According to Dynamic International Prognostic Scoring System plus(DIPSS-plus) risk
             grouping criteria, patients with medium-risk-2 or high-risk myelofibrosis were
             assessed,Patients with grade 1 medium-risk myelofibrosis with hepatosplenomegaly and
             no response to existing treatment and requiring treatment can also be enrolled;

          4. Patients who have received or are receiving Ruxolitinib,and：Ruxolitinib treatment time
             is not less than 28 days;Red blood cell transfusion is still needed during treatment
             with Ruxolitinib；or Ruxolitinib dose (including starting dose and adjusted dose)＜20mg
             bid，And must meet at least one of the following：Level 3 or higher platelet count
             reduction or Level 3 or higher anemia or Level 3 or higher hematoma/bleeding；

          5. a life expectancy &gt; 24 weeks;

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2；

          7. Splenomegaly: palpation of the splenic margin to or above the subcostal at least 5cm；

          8. Within 14 days before enrollment，The Laboratory indicators meet the following
             criteria：

               -  Absolute neutrophil count（ANC） &gt; 0.75 x 10^9/L，blood platelet count&gt; 30 x
                  10^9/L,And no colony stimulating factor was used within 7 days before screening;

               -  Peripheral blood blast &lt; 10%;

               -  AST和ALT≤3xULN，Patients with severe extramedullary hematopoiesis or who have
                  received iron therapy within 60 days prior to screening and thus have liver
                  function damage,AST和ALT≤5xULN ；

               -  Direct bilirubin≤2.0*ULN

               -  Creatinine clearance≥45mL/min；

          9. Meet the requirements of the Ethics Committee, voluntarily sign an informed consent
             form；

         10. Ability to follow research and follow-up procedures；

        Exclusion Criteria:

          1. Any significant clinical or laboratory abnormalities that the investigator considers
             to affect safety assessment, such as: a. uncontrolled diabetes (&gt; 250 mg/dL, or
             13.9&gt;mmol/L), b. had high blood pressure and antihypertensive drug treatment under two
             or unable to descend to the ranges (systolic blood pressure &lt; 160 mmHg, diastolic
             pressure &lt; 100 mmHg), c. peripheral neuropathy (NCI - CTC AE v5.0 standard grade 2 or
             above), etc;

          2. The patients who had a history of congestive heart failure(NCI - CTC AE v5.0 standard
             grade 3or above), uncontrollable or unstable angina or myocardial infarction,
             cerebrovascular accident or pulmonary embolism in the first 6 months;

          3. Screening of patients who have surgery within the first 4 weeks;

          4. Screening for patients with arrhythmia requiring treatment or QTc interval (QTcB)
             &gt;480ms;

          5. Screening for bacterial, viral, parasitic or fungal infections that require treatment;

          6. Patients which have with a history of congenital or acquired hemorrhagic
             diseases;(Note:With the exception of hematoma which caused by Ruxolitinib)

          7. Splenectomy patients or in the group carried out within three months before the spleen
             radiation treatment (including internal radiation and external radiation)

          8. Screening HIV, HBV DNA positive or higher than the normal reference range, or HCV RNA
             positive for HCV antibody;

          9. Women who are planning to become pregnant or who are pregnant or breast- feeding, as
             well as those who were unable to use effective contraceptives throughout the
             trial;Male patients who do not use condoms during the administration and within 2 days
             (approximately 5 half-lives) after the last administration;

         10. Patients who have suffered from malignant tumors (except cured basal cell carcinoma of
             the skin and carcinoma in situ of the cervix) in the past 5 years; Combined with other
             serious diseases, the researchers believe that patients' safety or compliance may be
             affected;

         11. With other serious diseases, the researchers think that may affect patient safety or
             compliance;

         12. The patients who had used the Jakatinib hydrochloride;

         13. Patients who have participated in the clinical trials of other new drugs or medical
             devices within the first 1 months;

         14. The patients who used the Hematopoietic growth factors within 14 days before Into the
             group (granulocyte growth factors, or platelet hormone) ；

         15. Patients who cannot cooperate with or cannot perform MRI or CT scans；

         16. Patients with refractory or recurrent myelofibrosis:

             refractory of myelofibrosis:After at least 28 days of adequate administration of JAK
             inhibitors, the spleen palpation was less than 15% smaller than before
             administration.Or at least 3 months later, the spleen volume on MRI/CT decreased by
             &lt;10% compared with that before the administration.

             Recurrence of myelofibrosis: after at least 3 months of taking adequate amount of JAK
             inhibitor, the spleen was enlarged again after shrinking compared with that before
             taking the drug, and compared with the minimum value during taking the drug, the
             spleen volume increased ≥10% on MRI/CT examination or ≥30% on spleen palpation.

         17. Any treatment MF medication (eg hydroxyurea,except ruxolitinib ), any immunomodulation
             used within 2 weeks prior to enrollment Agent (such as thalidomide), any
             immunosuppressant, glucocorticoids ≥ 10 mg/day of prednisone or equivalent biological
             strength, or patients within 6 half-life of the drug, over time Prevail;Patients who
             had received rucotinib within 1 week prior to enrolling
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Jin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital of Medical School of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Jin, MD</last_name>
    <phone>13505716779</phone>
    <email>jiej0503@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenjuan Yu, MD</last_name>
    <phone>13750853563</phone>
    <email>drwjyu@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Medical School of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Jin, MD</last_name>
      <phone>13505716779</phone>
      <email>jiej0503@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Wenjuan Yu, MD</last_name>
      <phone>13750853563</phone>
      <email>drwjyu@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 10, 2019</study_first_submitted>
  <study_first_submitted_qc>January 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share date of the trial</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

